A comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide vs abiraterone acetate in linked clinical and claims databases
Real-world study shows apalutamide leads to faster, deeper PSA90 response vs abiraterone in patients with de novo metastatic castration-sensitive prostate cancer.
